These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25526463)

  • 1. BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.
    Verlinden I; van den Hurk K; Clarijs R; Willig AP; Stallinga CMHA; Roemen GMJM; van den Oord JJ; Zur Hausen A; Speel EM; Winnepenninckx VJL
    Medicine (Baltimore); 2014 Dec; 93(28):e285. PubMed ID: 25526463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.
    Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
    JAMA Dermatol; 2015 Apr; 151(4):410-6. PubMed ID: 25588152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
    Piris A; Mihm MC; Hoang MP
    Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
    Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
    Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in Intrapatient Melanoma BRAFV600E Mutation Status.
    Riveiro-Falkenbach E; Santos-Briz A; Ríos-Martín JJ; Rodríguez-Peralto JL
    Am J Dermatopathol; 2017 Apr; 39(4):291-295. PubMed ID: 28323782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrapatient homogeneity of BRAFV600E expression in melanoma.
    Menzies AM; Lum T; Wilmott JS; Hyman J; Kefford RF; Thompson JF; O'Toole S; Long GV; Scolyer RA
    Am J Surg Pathol; 2014 Mar; 38(3):377-82. PubMed ID: 24335665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma.
    Feller JK; Yang S; Mahalingam M
    Mod Pathol; 2013 Mar; 26(3):414-20. PubMed ID: 23041829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFV600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma.
    Naimy S; Bzorek M; Eriksen JO; Dyring-Andersen B; Rahbek Gjerdrum LM
    Dermatology; 2023; 239(3):409-421. PubMed ID: 36657398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
    Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
    Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors.
    Riveiro-Falkenbach E; Villanueva CA; Garrido MC; Ruano Y; García-Martín RM; Godoy E; Ortiz-Romero PL; Ríos-Martín JJ; Santos-Briz A; Rodríguez-Peralto JL
    J Invest Dermatol; 2015 Dec; 135(12):3078-3085. PubMed ID: 26083553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutations are detectable in conjunctival but not uveal melanomas.
    Spendlove HE; Damato BE; Humphreys J; Barker KT; Hiscott PS; Houlston RS
    Melanoma Res; 2004 Dec; 14(6):449-52. PubMed ID: 15577314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
    Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
    Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF Heterogeneity in Melanoma.
    Ito T; Tanaka Y; Murata M; Kaku-Ito Y; Furue K; Furue M
    Curr Treat Options Oncol; 2021 Feb; 22(3):20. PubMed ID: 33558987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
    Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
    J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
    Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
    Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic findings in treatment-naïve and proton-beam-radiated iris melanomas.
    Krishna Y; Kalirai H; Thornton S; Damato BE; Heimann H; Coupland SE
    Br J Ophthalmol; 2016 Jul; 100(7):1012-1016. PubMed ID: 27098748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.
    Manfredi L; Meyer N; Tournier E; Grand D; Uro-Coste E; Rochaix P; Brousset P; Lamant L
    Acta Derm Venereol; 2016 Jun; 96(5):630-4. PubMed ID: 26695089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
    Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
    J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.